Drug Science Teams up with Medical Cannabis Provider to Improve Access

25th March 2020
By Emily Ledger

The Drug Science Medical Cannabis Working Group (MCWG) has announced a new partnership with a British medical cannabis producer. Avida Global will join up with Drug Science in an attempt to help improve access to medical cannabis products in the UK. 

MCWG was launched by Drug Science in 2019 as part of the body’s groundbreaking Project Twenty21. The group is made up of a collection of Drug Science experts, patient representatives, and policymakers.

Avida Global is a UK-based medical cannabis producer with cultivation operations in Colombia. The company currently produces CBD and full spectrum cannabis oils for medicinal uses. Avida aims to be a leading producer of cost-effective and environmentally sustainable medical cannabis.

David Kirby, CEO of Avida Global, said:

“Avida Global is delighted to partner with the Drug Science Medicinal Cannabis Working Group. Improving education, access and the quality of medicinal cannabis in the UK is critical to helping improve the lives of millions of people.”

Project Twenty21 is set to be Europe’s biggest medical cannabis patient registry, with an aim to recruit up to 20,000 patients by 2021. The partnership is aimed at accelerating medical cannabis access for patients of a variety of conditions including chronic pain, multiple sclerosis, and PTSD.

Drug Science CEO, David Badcock, said:

“We are delighted that Avida Global have joined the Drug Science Medical Cannabis Working Group. Our shared vision, which will accelerate access of medical cannabis to patients who need it the most, will be greatly enhanced by the support provided the Avida Global team.”

Medical cannabis was legalised in the UK in November 2018. However, patient access to the medication remains extremely low, with the majority of prescriptions being carried out by private clinics. Drug Science’s Project Twenty21 patient registry aims to collect the evidence needed to improve patient access to these medications in the future.


Related Stories

Would you like to know the results of our polls? Please complete the data request form by clicking here.

About the Author

Emily Ledger
Prior to joining the team at Canex, Emily studied Journalism at Sheffield Hallam University for three years. During her studies, she specialised in magazine and feature writing and went on to contribute to both the content and design departments at a local magazine. Emily is now the Head of Content at Canex where she has been both curating and contributing articles and content since the launch of the website.

Enjoying this article?

Join the thousands of subscribers who stay ahead of the game.

Advertise on Canex

Reach thousands of customers, as well as industry leaders and manufacturers
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on whatsapp

Subscribe to our newsletter

All the latest CBD news & updates, direct to your inbox
By submitting this form, you are giving Canex permission to contact you directly via email or telephone. You can opt out at any stage, and your contact data will never be shared with any 3rd party without your explicit consent. Our Privacy Policy.

Keeping subscribers up-to-date with news & insight within the CBD industry. From regulation and legislation reforms, industry updates and guides through the ongoing studies of the substance; to product news, reviews and guides.

© 2020 | Canex Group Ltd | All Rights Are Reserved